EP0967981A1 - Medicament contenant de la betasitosterine et/ou des melanges phytosterol-betasitosterine - Google Patents

Medicament contenant de la betasitosterine et/ou des melanges phytosterol-betasitosterine

Info

Publication number
EP0967981A1
EP0967981A1 EP98905304A EP98905304A EP0967981A1 EP 0967981 A1 EP0967981 A1 EP 0967981A1 EP 98905304 A EP98905304 A EP 98905304A EP 98905304 A EP98905304 A EP 98905304A EP 0967981 A1 EP0967981 A1 EP 0967981A1
Authority
EP
European Patent Office
Prior art keywords
betasitosterol
phytosterol
mixtures
remedy
betasitosteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98905304A
Other languages
German (de)
English (en)
Inventor
Horst Kief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Kief Lizenz Verwertungs GmbH
Original Assignee
Dr Kief Lizenz Verwertungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Kief Lizenz Verwertungs GmbH filed Critical Dr Kief Lizenz Verwertungs GmbH
Publication of EP0967981A1 publication Critical patent/EP0967981A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • the invention relates to a medicament which contains betasitosterol / phytosterol mixtures and / or betasitosterol and its physiological metabolites.
  • Solubility processes for the inherently poorly soluble betasitosterol in various oils, paraffins and glycerin have been found, which open up new indications for the use of these substances.
  • the esterification of betasitosterol with carboxylic acids also opens up therapeutic options for asthma, inflammatory bowel diseases, arterial hypertension, autoimmune diseases of the skin and for pain relief, which go far beyond the previously known spectrum of the use of betasitosterol or phytosterol / betasitosterol mixtures.
  • Naturally occurring phytosterols are usually a mixture of different sterols (e.g. campesterol, stigmasterol, etc.), the most important component of which is betasitosterol. For example, it can be used as an extract from plants and the like. a. Soybeans or saw palmetto fruits can be obtained by known methods. It has been used in medicine for two indications for decades:
  • the substance is practically non-toxic and interferes with the release of arachidonic acid from biomembranes, which inhibits inflammatory processes.
  • a disadvantage is their insolubility, so that they only have a resorption rate of about five percent in healthy subjects.
  • Another disadvantage is that at higher doses, such as those used to lower lipids, the absorption rate and thus the systemic bioavailability drops drastically. H. there is almost no resorption (saturation kinetics).
  • betasitosterol is extremely low in side effects. Even with oral doses of up to 24 g per day, there is only a blood level of 10 mg due to the low absorption rate. It is 60 to 75% glucoronidated in the organism and about 20% cholic acid (C 23 H 36 (OH) 3 COOH) and chenodeoxycholic acid (C 23 H 37 (OH) 2 COOH) metabolized. Intestinal bacteria further reduce cholic acid to deoxycholic acid.
  • betasitosterol and / or its physiological metabolites in diseases of the skin and subcutaneous tissue is unknown.
  • phytosterols in particular betasitosterol
  • betasitosterol are esterified, primarily with carboxylic acids and dicarboxylic acids.
  • solubility processes for phytosterol / betasitosteric mixtures have been found according to the invention, which have additional therapeutic applications, e.g. against skin diseases such as psoriasis and neurodermatitis.
  • Lactic acid, ascorbic acid, gluconic acid and tartaric acid are preferred for esterification due to their physiological effectiveness in the organism, their therapeutic safety and their freedom from side effects.
  • deoxycholic acid in neutral oil and in cottonseed oil corresponds approximately to that of betasitosterol.
  • Deoxycholic acid is also relatively readily water-soluble in the form of its alkali metal salts and in particular its sodium salt; the addition of sodium deoxycholate improves the solubility of betasitosterol in oil.
  • deoxycholic acid is added, both oils become opalescent.
  • solubility of phytosterol / betasitosteric mixtures and betasitosterin metabolites can be accelerated and significantly improved in terms of yield if the active ingredients are heated in oil, paraffins, stearates or petroleum jelly at temperatures of about 70 ° C to 160 ° C, advantageously at 120 ° C to 140 ° C, appropriately treated over a period of 30 minutes to 3 hours.
  • betasitosterol or sodium deoxycholate is heated to 120 ° C in various natural and mineral oils, paraffins, commercially available skin-friendly stearate mixtures or petroleum jelly (2 g substance in 100 ml), both substances dissolve completely within 90 minutes.
  • betasitosterol dissolves up to about 15% in taring mixes, paraffins, vegetable and mineral oil.
  • sodium deoxycholate remains clearly dissolved in oil, while betasitosterol becomes slightly opalescent in oil.
  • betasitosterol and sodium deoxycholate can be introduced into glycerol.
  • both substances dissolve completely clearly when heated to 120 ° C.
  • the betasitosterol-glycerol solution is slightly opalescent, while sodium deoxycholate remains clear here too.
  • a particular advantage of the betasitosterol-glycerin mixture is its water solubility.
  • the esters of betasitosterol with carboxylic acids, in particular with ascorbic acid or lactic acid, are also water-soluble.
  • the esterification of betasitosterol with carboxylic acid also has the advantage that the excess carboxylic acid components are relatively acidic and, as ointment components, are a valuable aid in maintaining the protective acid mantle of the skin.
  • the esterification with carboxylic and dicarboxylic acids takes place according to known processes. In the same way, according to the prior art, the formation of saturated, mono- and polyunsaturated oleic acid esters, stearic acid esters and triglycerides with unesterified residual fractions can be carried out using acid catalysis.
  • betasitosterol oleic acid or stearic acid esters on the one hand, glycerin, ascorbic acid and lactic acid esters on the other hand, makes it possible to apply cortisone-like structures to the skin both in fat-soluble form and in water-soluble preparation, and thus good diffusion through the upper layers of the skin to ensure.
  • Phytosterol / betasitosteric mixtures if they are dissolved in oil in the form described above, alone or in a mixture with sodium deoxycolate in aqueous solution in a concentration of 0.5 to 2.0%, are stirred into an ointment base and applied to the skin the itching in neurodermatitis usually subsides after 2 - 5 minutes. Inflammatory processes with redness and swelling are alleviated after 24 to 48 hours. A histamine-antagonistic as well as a cortisone-like effect is thus found, but without the side effects of this hormone.
  • psoriasis In psoriasis (psoriasis), even in extreme cases, the formation of dandruff is often reduced 24 hours after the first application, especially when using the metabolite deoxycholic acid.
  • the use of the substances mentioned is completely unproblematic, in contrast to an ointment with a component of a structure similar to vitamin D, which is due to the absorption of the molecule similar to vitamin D because of the The risk of overdosing and thus influencing the calcium metabolism can only be applied to a limited extent.
  • betasitosterol or deoxycholic acid in the form of alkali alkoxycholates, especially sodium deoxycholate or both substances are applied together in a resorbable ointment or gel base on inflammatory swellings or in the case of arthrosis, arthritis or soft tissue rheumatism, a lasting pain reduction and swelling of the inflamed areas will be achieved within 2 - 3 Days.
  • One of the first steps in triggering pain is the release of mediators of the prostaglandin cascade through inflammatory processes. In this sense, the substance acts promptly and inhibits pain both in rheumatics and in patients with malignant diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne un médicament contenant des mélanges bétasitostérine-phytostérol ou de la bétasitostérine et ses métabolites physiologiques. On a trouvé des processus d'amélioration de la solubilité de la bétasitostérine, qui est en soit difficilement soluble, dans différentes huiles, et dans la glycérine, ces processus offrant de nouvelles possibilités d'utilisation de ces substances. L'estérification de la bétasitostérine avec des acides carboxyliques offre en outre d'autres possibilités thérapeutiques en ce qui concerne l'asthme, les maladies intestinales inflammatoires, l'hypertension artérielle, les maladies auto-immunes de la peau, ainsi que pour la lutte contre la douleur, ces possibilités dépassant de beaucoup les limites du spectre, connu depuis longtemps, d'utilisation de la bétasitostérine ou des mélanges phytostérol-bétasitostérine.
EP98905304A 1997-01-16 1998-01-16 Medicament contenant de la betasitosterine et/ou des melanges phytosterol-betasitosterine Withdrawn EP0967981A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19701264 1997-01-16
DE19701264A DE19701264A1 (de) 1997-01-16 1997-01-16 Heilmittel, enthaltend Betasitosterin und/oder Phytosterol/Betasitosteringemische
PCT/EP1998/000227 WO1998031372A1 (fr) 1997-01-16 1998-01-16 Medicament contenant de la betasitosterine et/ou des melanges phytosterol-betasitosterine

Publications (1)

Publication Number Publication Date
EP0967981A1 true EP0967981A1 (fr) 2000-01-05

Family

ID=7817498

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98905304A Withdrawn EP0967981A1 (fr) 1997-01-16 1998-01-16 Medicament contenant de la betasitosterine et/ou des melanges phytosterol-betasitosterine

Country Status (5)

Country Link
US (1) US6407085B1 (fr)
EP (1) EP0967981A1 (fr)
AU (1) AU6094598A (fr)
DE (1) DE19701264A1 (fr)
WO (1) WO1998031372A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI974648A (fi) 1997-09-09 1999-05-06 Raisio Benecol Oy Hydroksihappo-, maitohappo- ja hydroksialkanoaattiesterit ja niiden käyttö
FI115527B (fi) * 1998-10-16 2005-05-31 Upm Kymmene Oyj Kasvisterolijohdannaisten käyttö ja niitä sisältäviä tuotteita
CN1237071C (zh) * 1999-06-23 2006-01-18 福布斯医药技术股份有限公司 植物甾醇或植物甾烷醇的抗坏血酸衍生物及其组合物、食品和用途
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
US7615546B2 (en) * 2005-08-19 2009-11-10 Bioderm Research Topical delivery system for phytosterols
KR102527103B1 (ko) 2016-06-06 2023-04-28 크리스탈 파마 에스.에이.유. 디옥시콜린산 제조방법 및 디옥시콜린산의 제조에 유용한 중간물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004043A (en) * 1959-10-09 1961-10-10 Eastman Kodak Co Water-soluble vegetable oil sterol derivatives
US4254111A (en) * 1978-07-05 1981-03-03 Roecar Holdings (Netherlands Antilles) Nv Sterolin products
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
JPS57131716A (en) * 1981-01-28 1982-08-14 Hiroshi Sekimoto Cosmetic for exclusive use to plantar skin
AU2272883A (en) * 1982-12-22 1984-06-28 Herpes Pharmaceutical Inc. Pharmaceutical compositions of steriods for treatment of herpes simplex infections
SU1138162A1 (ru) * 1983-04-28 1985-02-07 Ленинградская Ордена Ленина Лесотехническая Академия Им.С.М.Кирова Крем дл губ
DE3416112A1 (de) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
US4897224A (en) * 1985-03-05 1990-01-30 Morinaga Milk Industry Co., Ltd. Method for producing ferulyl stanol derivatives
DE3546360A1 (de) * 1985-12-30 1987-07-23 Mueller Karl Heinz Dr Verwendung von desoxycholsaeure bei wundheilungsstoerungen
JPS63156727A (ja) * 1986-12-19 1988-06-29 Q P Corp 皮ふ疾患治療剤及びそれを使用した絆創膏
JPH0225425A (ja) * 1988-07-13 1990-01-26 Nippon Ham Kk 降圧剤
DE3829641A1 (de) * 1988-09-01 1990-03-15 Roecar Holdings Nv Transdermal anwendbare pharmazeutische zubereitungen mit sterolinen und/oder spiroketalinen
JP2819140B2 (ja) * 1989-01-18 1998-10-30 ポーラ化成工業株式会社 化粧料
US5574063A (en) * 1989-10-12 1996-11-12 Perricone; Nicholas V. Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage
GB2238476A (en) * 1989-11-04 1991-06-05 K T Lalvani Therapeutic aquatic animal and garlic products
ATE142883T1 (de) * 1991-03-28 1996-10-15 Rooperol Na Nv Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren
EP0508756B1 (fr) * 1991-04-09 1996-10-23 Takeda Chemical Industries, Ltd. Préparation stabilisée de vitamine D
CH680704A5 (fr) * 1991-05-15 1992-10-30 Medichemie Ag
RU2069557C1 (ru) * 1992-01-31 1996-11-27 ТОО "Фитолон" Крем для кожи
JP2983125B2 (ja) * 1993-06-02 1999-11-29 株式会社ノエビア 皮膚外用剤
DE4328799A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Verfahren zur Gewinnung von pharmakologisch wirksamen Verbindungen aus komplexen Stoffgemischen
JP3126583B2 (ja) * 1994-01-13 2001-01-22 ロンシャン シュ 熱傷治療剤、その製造方法及びそれを用いた治療方法
JPH07277986A (ja) * 1994-04-08 1995-10-24 Kazuo Hosoya 胆汁酸塩を主成分とするメチシリン耐性黄色ブドウ球菌用抗菌 剤成分
JP3493459B2 (ja) * 1994-05-17 2004-02-03 株式会社大塚製薬工場 皮膚外用剤
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
JP2978432B2 (ja) * 1995-12-21 1999-11-15 日誠マリン工業株式会社 抗核抗体減少用医薬組成物及びリウマチ因子減少用医薬組成物
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9831372A1 *

Also Published As

Publication number Publication date
US6407085B1 (en) 2002-06-18
US20020035133A1 (en) 2002-03-21
DE19701264A1 (de) 1998-07-23
WO1998031372A1 (fr) 1998-07-23
AU6094598A (en) 1998-08-07

Similar Documents

Publication Publication Date Title
DE2660069C2 (fr)
DE69924740T2 (de) Klare wässrige lösungen enthaltend gallensäuren
DE4133694C2 (de) Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
DE3205504C2 (de) Äußerlich anwendbares, Ibuprofen enthaltendes Arzneimittel
DE3438630A1 (de) Kombinierte fettsaeurezusammensetzung zur senkung des cholesterin- und triglycerid-blutspiegels
DE69724629T2 (de) Zusammensetzungen und deren verwendungen
EP1267900A1 (fr) Emulsion contenant un extrait de plante, procede pour produire cette emulsion et pour obtenir cet extrait de plante
DE2621214C3 (de) Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3621306A1 (de) Amphiphile, lipidartige verbindungen, verfahren zu deren herstellung und diese verbindungen enthaltende kosmetische und dermopharmazeutische mittel
DE2707878C2 (de) Verwendung von Mono- und/oder Diglyceriden mittelkettiger Fettsäuren
EP0967981A1 (fr) Medicament contenant de la betasitosterine et/ou des melanges phytosterol-betasitosterine
DE3829641C2 (fr)
DE19534209A1 (de) Hormonales Mittel zur Behandlung der Haut
DE2759171C2 (fr)
DE3430366C2 (fr)
DE60213794T2 (de) Hautpräparat
DE2851544A1 (de) Corticosteroidhaltige creme
DE2654743A1 (de) Therapeutikum zur externen behandlung von schuppenflechte (psoriasis), flechten und ekzemen
EP0455631B1 (fr) Preparation contenant de l'acide salicylique pour traiter des affections dermiques desquamantes
DE4310015A1 (de) Mittel zur Pflege der menschlichen Haut
DE2161588A1 (de) Mittel zur behandlung von hyperlipoproteinaemien und verfahren zu seiner herstellung
DE2934090A1 (de) Therapie der hyperkeratotischen hauterkrankungen.
DE1767094C3 (de) Veränderung des Fettstoffwechsels sowie Reduzierung des Blutcholesterinspiegels
EP1503729B1 (fr) Composition et son utilisation comme formulation pharmaceutique ou cosmetique pour application externe
DE2033629C3 (de) Oral verabreichbares Mittel zur Erniedrigung des Serum-Lipidspiegels bei Menschen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT DE ES FR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20000707